Our eQTL study together with a comprehensive analysis of tens of independent clinical data sets highlight the potential role of CCND2 as a plausible causative gene with metastatic tumor suppressive activity in aggressive prostate cancer, providing promising clues on risk stratification and targeted therapy in men with advanced prostate cancer. The gene discussed is CCND2; the disease is Familial prostate cancer.